S&P 500   4,338.30 (-1.45%)
DOW   34,107.32 (-0.97%)
QQQ   358.58 (-1.63%)
AAPL   174.34 (-0.66%)
MSFT   320.77 (+0.00%)
META   296.80 (-0.96%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.48 (-3.85%)
BABA   84.26 (-1.73%)
AMD   96.02 (-4.31%)
T   15.32 (-1.48%)
F   12.21 (-1.21%)
MU   68.18 (-2.15%)
CGC   0.77 (-11.40%)
GE   113.35 (-1.31%)
DIS   82.70 (+0.17%)
AMC   7.74 (-5.15%)
PFE   32.88 (-2.20%)
PYPL   58.80 (-3.38%)
NFLX   384.31 (-0.52%)
S&P 500   4,338.30 (-1.45%)
DOW   34,107.32 (-0.97%)
QQQ   358.58 (-1.63%)
AAPL   174.34 (-0.66%)
MSFT   320.77 (+0.00%)
META   296.80 (-0.96%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.48 (-3.85%)
BABA   84.26 (-1.73%)
AMD   96.02 (-4.31%)
T   15.32 (-1.48%)
F   12.21 (-1.21%)
MU   68.18 (-2.15%)
CGC   0.77 (-11.40%)
GE   113.35 (-1.31%)
DIS   82.70 (+0.17%)
AMC   7.74 (-5.15%)
PFE   32.88 (-2.20%)
PYPL   58.80 (-3.38%)
NFLX   384.31 (-0.52%)
S&P 500   4,338.30 (-1.45%)
DOW   34,107.32 (-0.97%)
QQQ   358.58 (-1.63%)
AAPL   174.34 (-0.66%)
MSFT   320.77 (+0.00%)
META   296.80 (-0.96%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.48 (-3.85%)
BABA   84.26 (-1.73%)
AMD   96.02 (-4.31%)
T   15.32 (-1.48%)
F   12.21 (-1.21%)
MU   68.18 (-2.15%)
CGC   0.77 (-11.40%)
GE   113.35 (-1.31%)
DIS   82.70 (+0.17%)
AMC   7.74 (-5.15%)
PFE   32.88 (-2.20%)
PYPL   58.80 (-3.38%)
NFLX   384.31 (-0.52%)
S&P 500   4,338.30 (-1.45%)
DOW   34,107.32 (-0.97%)
QQQ   358.58 (-1.63%)
AAPL   174.34 (-0.66%)
MSFT   320.77 (+0.00%)
META   296.80 (-0.96%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.48 (-3.85%)
BABA   84.26 (-1.73%)
AMD   96.02 (-4.31%)
T   15.32 (-1.48%)
F   12.21 (-1.21%)
MU   68.18 (-2.15%)
CGC   0.77 (-11.40%)
GE   113.35 (-1.31%)
DIS   82.70 (+0.17%)
AMC   7.74 (-5.15%)
PFE   32.88 (-2.20%)
PYPL   58.80 (-3.38%)
NFLX   384.31 (-0.52%)
OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Forecast, Price & News

$34.00
0.00 (0.00%)
(As of 09/20/2023 ET)
Compare
Today's Range
$34.00
$34.00
50-Day Range
$29.53
$34.34
52-Week Range
$21.35
$34.34
Volume
187 shs
Average Volume
281 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
0.68%
Price Target
$30.60

Ipsen MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
10.0% Downside
$30.60 Price Target
Short Interest
Healthy
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.57mentions of Ipsen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.36%
From $2.51 to $2.77 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars


IPSEY stock logo

About Ipsen (OTCMKTS:IPSEY) Stock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

IPSEY Price History

IPSEY Stock News Headlines

The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Ipsen (OTCMKTS:IPSEY) Upgraded to Buy at UBS Group
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Ipsen Shares Rise After It Upgrades 2023 Outlook
See More Headlines
Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Company Calendar

Ex-Dividend for 6/27 Dividend
6/02/2023
Dividend Payable
6/27/2023
Today
9/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.60
High Stock Price Forecast
$30.60
Low Stock Price Forecast
$30.60
Forecasted Upside/Downside
-10.0%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.33 billion
Cash Flow
$3.51 per share
Book Value
$9.72 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.98
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. David Loew (Age 56)
    MD, CEO & Director
    Comp: $2.38M
  • Mr. Aymeric Le Chatelier (Age 54)
    Exec. VP & Group CFO
  • Dr. Aidan Murphy Ph.D. (Age 57)
    Exec. VP of Technical Operations
  • Mr. Craig Marks
    Vice-Pres of Investor Relations
  • Mr. Francois Garnier (Age 61)
    Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer
  • Ms. Gwenan White
    Exec. VP of Communications, Public Affairs & Sustainability
  • Mr. Regis Mulot (Age 57)
    Exec. VP & Chief HR Officer
  • Ms. Dominique Bery (Age 52)
    Head of Nordics & Baltics
  • Dr. Yan Moore M.D. (Age 56)
    Sr. VP & Head of Oncology Therapeutic Area
  • Dr. Alexander McEwan
    Vice-Pres & Head of Radiopharmaceuticals













IPSEY Stock - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View IPSEY analyst ratings
or view top-rated stocks.

What is Ipsen's stock price forecast for 2023?

8 Wall Street analysts have issued 12 month target prices for Ipsen's stock. Their IPSEY share price forecasts range from $30.60 to $30.60. On average, they anticipate the company's share price to reach $30.60 in the next year. This suggests that the stock has a possible downside of 10.0%.
View analysts price targets for IPSEY
or view top-rated stocks among Wall Street analysts.

How have IPSEY shares performed in 2023?

Ipsen's stock was trading at $26.88 at the beginning of the year. Since then, IPSEY shares have increased by 26.5% and is now trading at $34.00.
View the best growth stocks for 2023 here
.

Are investors shorting Ipsen?

Ipsen saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 100 shares, a decrease of 50.0% from the August 15th total of 200 shares. Based on an average daily volume of 800 shares, the short-interest ratio is presently 0.1 days.
View Ipsen's Short Interest
.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen announced a dividend on Thursday, June 1st. Stockholders of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23.
Read our dividend analysis for IPSEY
.

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.68%.
Read our dividend analysis for IPSEY.

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $34.00.

How many employees does Ipsen have?

The company employs 5,300 workers across the globe.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01.

This page (OTCMKTS:IPSEY) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -